Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Migraine

  Free Subscription


Articles published in Cephalalgia

Retrieve available abstracts of 316 articles:
HTML format



Single Articles


    May 2024
  1. RASMUSSEN AV, Jensen RH, Gantenbein A, Sumelahti ML, et al
    Consensus recommendations on the role of nurses in headache care: A European e-Delphi study.
    Cephalalgia. 2024;44:3331024241252161.
    PubMed     Abstract available


    April 2024
  2. RATTANAWONG W, Rapoport A, Srikiatkhachorn A
    Medication "underuse" headache.
    Cephalalgia. 2024;44:3331024241245658.
    PubMed     Abstract available


  3. MITTER VR, Lupattelli A, Bjork MH, Nordeng HME, et al
    Identification and characterization of migraine in pregnancy: A Norwegian registry-based cohort study.
    Cephalalgia. 2024;44:3331024241248846.
    PubMed     Abstract available


  4. GARCIA-AZORIN D, Martinez-Badillo C, Camina Muniz J, Gago-Veiga AB, et al
    CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.
    Cephalalgia. 2024;44:3331024241248833.
    PubMed     Abstract available


  5. WHITAKER DJ, Dumkrieger GM, Hentz JG, Dodick DW, et al
    Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine.
    Cephalalgia. 2024;44:3331024241249747.
    PubMed     Abstract available


  6. CROOP R, Berman G, Kudrow D, Mullin K, et al
    A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
    Cephalalgia. 2024;44:3331024241232944.
    PubMed     Abstract available


  7. OLFAT M, Hosseinpour S, Masoumi S, Gogia Rastogi R, et al
    A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial.
    Cephalalgia. 2024;44:3331024241230963.
    PubMed     Abstract available


    March 2024
  8. PASCUAL-MATO M, Garate G, de Prado-Tejerina C, Garcia MJ, et al
    Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study.
    Cephalalgia. 2024;44:3331024241233979.
    PubMed     Abstract available


  9. SELNTIGIA A, Exacoustos C, Ortoleva C, Russo C, et al
    Correlation between endometriosis and migraine features: Results from a prospective case-control study.
    Cephalalgia. 2024;44:3331024241235210.
    PubMed     Abstract available


  10. PORRECA F, Navratilova E, Hirman J, van den Brink AM, et al
    Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Cephalalgia. 2024;44:3331024241238153.
    PubMed     Abstract available


  11. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
    Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.
    Cephalalgia. 2024;44:3331024241237247.
    PubMed     Abstract available


  12. LAMAS PEREZ R, Millan-Vazquez M, Gonzalez-Oria C
    Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
    Cephalalgia. 2024;44:3331024231226181.
    PubMed     Abstract available


  13. SACCO S, Porreca F
    Breaking barriers in migraine care: Advancing gender medicine to bridge the gap for men.
    Cephalalgia. 2024;44:3331024241238157.
    PubMed    


  14. DIENER HC, May A
    New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication.
    Cephalalgia. 2024;44:3331024241228605.
    PubMed     Abstract available


  15. ASHINA H, Diener HC, Tassorelli C, Scher AI, et al
    Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury.
    Cephalalgia. 2024;44:3331024241234068.
    PubMed     Abstract available


    February 2024
  16. TORRES-FERRUS M, Gallardo VJ, Alpuente A, Caronna E, et al
    Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
    Cephalalgia. 2024;44:3331024231222923.
    PubMed     Abstract available


  17. THURAIAIYAH J, Ashina H, Christensen RH, Al-Khazali HM, et al
    Premonitory symptoms in migraine: A REFORM Study.
    Cephalalgia. 2024;44:3331024231223979.
    PubMed     Abstract available


  18. PHILLIPS K, Clerkin-Oliver C, Nirantharakumar K, Crowe FL, et al
    How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis.
    Cephalalgia. 2024;44:3331024241229410.
    PubMed     Abstract available


  19. VIANA M, Hougaard A, Tronvik E, Winnberg IG, et al
    Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura.
    Cephalalgia. 2024;44:3331024241234809.
    PubMed     Abstract available


  20. IKUMI N, Marti-Marca A, Torre-Sune A, Cerda-Company X, et al
    Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study.
    Cephalalgia. 2024;44:3331024241230279.
    PubMed     Abstract available


  21. TASSORELLI C, Onishchenko K, Halker Singh RB, Duan M, et al
    Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Cephalalgia. 2024;44:3331024241235156.
    PubMed     Abstract available


  22. SHEWALE AR, Brandenburg JA, Burslem K, Lipton RB, et al
    Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine.
    Cephalalgia. 2024;44:3331024241235139.
    PubMed     Abstract available


    January 2024
  23. COPPOLA G, Renzo AD, Parisi V, Serrao M, et al
    Comment on "Lack of reproducibility of resting-state functional MRI findings in migraine with aura".
    Cephalalgia. 2024;44:3331024231225186.
    PubMed    


  24. PICO MJ, Badri M, Michalak N, Siefferman JW, et al
    Systemic allergic reaction to galcanezumab (emgality): a case report.
    Cephalalgia. 2024;44:3331024231222914.
    PubMed     Abstract available


  25. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
    Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses.
    Cephalalgia. 2024;44:3331024231222637.
    PubMed     Abstract available


  26. BUGGE NS, Grotta Vetvik K, Alstadhaug KB, Braaten T, et al
    Cumulative exposure to estrogen may increase the risk of migraine in women.
    Cephalalgia. 2024;44:3331024231225972.
    PubMed     Abstract available


  27. FLORESCU AM, Lannov LV, Younis S, Cullum CK, et al
    No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
    Cephalalgia. 2024;44:3331024231222915.
    PubMed     Abstract available


  28. RAHMAN SM, Luebke AE
    Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models.
    Cephalalgia. 2024;44:3331024231223971.
    PubMed     Abstract available


  29. RAFFAELLI B, Do TP, Chaudhry BA, Amin FM, et al
    Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial.
    Cephalalgia. 2024;44:3331024231222916.
    PubMed     Abstract available


  30. MONTE G, Papetti L, Ursitti F, Sforza G, et al
    Childhood primary stabbing headache: A double center study.
    Cephalalgia. 2024;44:3331024231225974.
    PubMed     Abstract available


  31. KRISTOFFERSEN ES, Pallesen S, Waage S, Bjorvatn B, et al
    The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study.
    Cephalalgia. 2024;44:3331024231226323.
    PubMed     Abstract available


    December 2023
  32. BASEDAU H, Ornello R, Matteis E, Davaasuren B, et al
    Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?
    Cephalalgia. 2023;43:3331024231218392.
    PubMed     Abstract available


  33. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
    The evolutionary meaning of migraine.
    Cephalalgia. 2023;43:3331024231209303.
    PubMed     Abstract available


  34. TEZUKA T, Shibata M, Hanaoka H, Izawa Y, et al
    Systemic lupus erythematosus mimicking retinal migraine: a case report.
    Cephalalgia. 2023;43:3331024231219477.
    PubMed     Abstract available


  35. DOBOS D, Kokonyei G, Gyebnar G, Szabo E, et al
    Microstructural differences in migraine: A diffusion-tensor imaging study.
    Cephalalgia. 2023;43:3331024231216456.
    PubMed     Abstract available


  36. AL-KARAGHOLI MA
    Targeting CGRP pathways and aura: A peripheral site with a central effect.
    Cephalalgia. 2023;43:3331024231212895.
    PubMed     Abstract available


  37. CHRISTOPHERSEN P, Dyhring T
    The shortcoming of using glibenclamide in exploratory clinical headache provocation studies.
    Cephalalgia. 2023;43:3331024231219475.
    PubMed     Abstract available


    November 2023
  38. VAN DER AREND B, Terwindt GM
    Response to Letter to the Editor, Comment on "Effect of COVID vaccinations on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208123.
    PubMed    


  39. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on "Effect of COVID vaccination on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208121.
    PubMed    


  40. AL-KHAZALI HM, Christensen RH, Dodick DW, Chaudhry BA, et al
    Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache.
    Cephalalgia. 2023;43:3331024231210930.
    PubMed     Abstract available


  41. NAVARRO-PEREZ MP, Santos-Lasaosa S, Olesen J
    Evaluation of the ICHD-3 diagnostic criteria for cardiac cephalalgia and new proposal.
    Cephalalgia. 2023;43:3331024231202243.
    PubMed     Abstract available


  42. HOUGAARD A, Gaist D, Garde E, Iversen P, et al
    Lack of reproducibility of resting-state functional MRI findings in migraine with aura.
    Cephalalgia. 2023;43:3331024231212574.
    PubMed     Abstract available


  43. BAHRA A
    Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment.
    Cephalalgia. 2023;43:3331024231214239.
    PubMed     Abstract available


  44. GARCIA-AZORIN D, Santana-Lopez L, Lozano-Alonso JE, Ordax-Diez A, et al
    InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection.
    Cephalalgia. 2023;43:3331024231212900.
    PubMed     Abstract available


  45. ASHINA M, Mitsikostas DD, Amin FM, Kokturk P, et al
    Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
    Cephalalgia. 2023;43:3331024231214987.
    PubMed     Abstract available


    October 2023
  46. SEBASTIANELLI G, Casillo F, Abagnale C, Renzo AD, et al
    Central sensitization mechanisms in chronic migraine with medication overuse headache: a study of thalamocortical activation and lateral cortical inhibition.
    Cephalalgia. 2023;43:3331024231202240.
    PubMed     Abstract available


  47. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
    An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study.
    Cephalalgia. 2023;43:3331024231206375.
    PubMed     Abstract available


  48. DEV P, Favas TT, Jaiswal R, Cyriac M, et al
    The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial.
    Cephalalgia. 2023;43:3331024231182684.
    PubMed     Abstract available


  49. CHUANG CH, Li JY, King JT, Chen WT, et al
    Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study.
    Cephalalgia. 2023;43:3331024231206781.
    PubMed     Abstract available


  50. CHRISTENSEN RH, Eigenbrodt AK, Ashina H, Steiner TJ, et al
    What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies.
    Cephalalgia. 2023;43:3331024231206376.
    PubMed     Abstract available


  51. KUAN AS, Chen SP, Wang YF, Wang SJ, et al
    Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
    Cephalalgia. 2023;43:3331024231208110.
    PubMed     Abstract available


  52. ZLOOF Y, Tsur AM, Simchoni M, Derazne E, et al
    Body mass index and migraine in adolescence: A nationwide study.
    Cephalalgia. 2023;43:3331024231209309.
    PubMed     Abstract available


  53. ALEKSOVSKA K, Hershey AD, Deen M, Icco R, et al
    Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
    Cephalalgia. 2023;43:3331024231206162.
    PubMed     Abstract available


  54. BELIN AC, Barloese MC
    The genetics and chronobiology of cluster headache.
    Cephalalgia. 2023;43:3331024231208126.
    PubMed     Abstract available


    September 2023
  55. VAN DER AREND BWH, Bloemhof MM, van der Schoor AG, van Zwet EW, et al
    Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study.
    Cephalalgia. 2023;43:3331024231198792.
    PubMed     Abstract available


    August 2023
  56. ALPUENTE A, Torre-Sune A, Caronna E, Gine-Cipres E, et al
    Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
    Cephalalgia. 2023;43:3331024231177636.
    PubMed     Abstract available


  57. LA ROCCA M, Laporta A, Clemente L, Ammendola E, et al
    Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients.
    Cephalalgia. 2023;43:3331024231189751.
    PubMed     Abstract available


  58. ADAM I, Elmugabil A, AlHabardi N
    History of maternal migraine and its association with preeclampsia: A case-control study in a low-resource setting in Sudan, Africa.
    Cephalalgia. 2023;43:3000605231193823.
    PubMed     Abstract available


  59. PULEDDA F, Vigano A, Sebastianelli G, Parisi V, et al
    Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review.
    Cephalalgia. 2023;43:3331024231195780.
    PubMed     Abstract available


  60. LIPTON RB, Halker Singh RB, Mechtler L, McVige J, et al
    Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Cephalalgia. 2023;51:3331024231190296.
    PubMed     Abstract available


    July 2023
  61. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
    Symptoms associated with headache in youth.
    Cephalalgia. 2023;43:3331024231187162.
    PubMed     Abstract available


    June 2023
  62. VERHAGEN IE, van der Arend BW, van Casteren DS, Thiermann NJ, et al
    Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study.
    Cephalalgia. 2023;43:3331024231164322.
    PubMed     Abstract available


  63. PELZER N, de Boer I, van den Maagdenberg AMJM, Terwindt GM, et al
    Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives.
    Cephalalgia. 2023;43:3331024231180564.
    PubMed     Abstract available


  64. KLAN T, Gaul C, Liesering-Latta E, Witthoft M, et al
    Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial.
    Cephalalgia. 2023;43:3331024231178237.
    PubMed     Abstract available


  65. BERTZ R, Bhardwaj R, Morris BA, Ashbrenner E, et al
    A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
    Cephalalgia. 2023;43:3331024231179131.
    PubMed     Abstract available


  66. BUTURE A, Tomkins EM, Shukralla A, Troy E, et al
    Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the
    Cephalalgia. 2023;43:3331024231182126.
    PubMed     Abstract available


  67. ADAMS AM, Buse DC, Leroux E, Lanteri-Minet M, et al
    Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.
    Cephalalgia. 2023;43:3331024231180611.
    PubMed     Abstract available


  68. CARCEL C, Haghdoost F, Shen J, Nanda P, et al
    The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231183166.
    PubMed     Abstract available


  69. THOMSEN AV, Puonti O, Gaist D, Kyvik KO, et al
    Investigations of the subarachnoid space as a potential link between aura and headache in migraine: A case-control MRI study.
    Cephalalgia. 2023;43:3331024231170541.
    PubMed     Abstract available


  70. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
    The prevalence and burden of medication overuse headache in Greece.
    Cephalalgia. 2023;43:3331024231184909.
    PubMed     Abstract available


    May 2023
  71. VAN DER AREND BWH, Verhagen IE, van Leeuwen M, van der Arend MQTP, et al
    Defining migraine days, based on longitudinal E-diary data.
    Cephalalgia. 2023;43:3331024231166625.
    PubMed     Abstract available


  72. CHEEMA S, Mehta D, Ray JC, Hutton EJ, et al
    New daily persistent headache: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231168089.
    PubMed     Abstract available


  73. STUBBERUD A, Ingvaldsen SH, Brenner E, Winnberg I, et al
    Forecasting migraine with machine learning based on mobile phone diary and wearable data.
    Cephalalgia. 2023;43:3331024231169244.
    PubMed     Abstract available


  74. ASHINA M, Lanteri-Minet M, Ettrup A, Christoffersen CL, et al
    Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
    Cephalalgia. 2023;43:3331024231170807.
    PubMed     Abstract available


  75. VAN WELIE RF, van Welie FC, de Vries Lentsch S, Dahan A, et al
    Characterizing opioid use in a Dutch cohort with migraine.
    Cephalalgia. 2023;43:3331024231174160.
    PubMed     Abstract available


  76. HSIAO FJ, Chen WT, Wang YF, Chen SP, et al
    Identification of patients with chronic migraine by using sensory-evoked oscillations from the electroencephalogram classifier.
    Cephalalgia. 2023;43:3331024231176074.
    PubMed     Abstract available


  77. GULDIKEN YC, Petropoulos IN, Malik A, Malik RA, et al
    Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine.
    Cephalalgia. 2023;43:3331024231170810.
    PubMed     Abstract available


  78. RUSCHEWEYH R, Dresler T, Forderreuther S, Gaul C, et al
    What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry.
    Cephalalgia. 2023;43:3331024231174855.
    PubMed     Abstract available


  79. STEINER TJ
    Classification of migraine and tension-type headache: A response to the proposals of Olesen.
    Cephalalgia. 2023;43:3331024231169240.
    PubMed    


  80. SUZUKI K, Suzuki S, Shiina T, Tatsumoto M, et al
    Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Cephalalgia. 2023;43:3331024231177649.
    PubMed     Abstract available


  81. PARK CG, Na HY, Park DE, Kim HY, et al
    Altered interictal serum histamine and immunoglobulin E but unchanged tryptase levels in individuals with episodic and chronic migraine.
    Cephalalgia. 2023;43:3331024231178218.
    PubMed     Abstract available


  82. ABU-ARAFEH I, Hershey AD, Diener HC, Tassorelli C, et al
    Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition - An experience-based update.
    Cephalalgia. 2023;43:3331024231178239.
    PubMed     Abstract available


    April 2023
  83. GIRI S, Tronvik E, Linde M, Pedersen SA, et al
    Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231156922.
    PubMed     Abstract available


  84. OLESEN J, Jensen RH
    The Global Campaign Against Headache and its future relation to IHS and WHO.
    Cephalalgia. 2023;43:3331024231159625.
    PubMed     Abstract available


  85. HAGHDOOST F, Puledda F, Garcia-Azorin D, Huessler EM, et al
    Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Cephalalgia. 2023;43:3331024231159366.
    PubMed     Abstract available


  86. NIDDAM DM, Wu SW, Lai KL, Yang YY, et al
    An altered reward system characterizes chronic migraine with medication overuse headache.
    Cephalalgia. 2023;43:3331024231158088.
    PubMed     Abstract available


  87. ASAWAVICHIENJINDA T, Sathitratanacheewin S, Chokesuwattanaskul R
    "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials.
    Cephalalgia. 2023;43:3331024231161261.
    PubMed     Abstract available


  88. IANNONE LF, Burgalassi A, Vigani G, Tabasso G, et al
    Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
    Cephalalgia. 2023;43:3331024231160519.
    PubMed     Abstract available


  89. FAVONI V, Mascarella D, Giannini G, Bauleo S, et al
    Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in Italy: The SPARTACUS study.
    Cephalalgia. 2023;43:3331024231157677.
    PubMed     Abstract available


  90. ASHINA M, Roos C, Li LQ, Komori M, et al
    Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
    Cephalalgia. 2023;43:3331024231161745.
    PubMed     Abstract available


  91. ZHANG L, Zhou Y, Wang Y, Yang L, et al
    Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model.
    Cephalalgia. 2023;43:3331024231163131.
    PubMed     Abstract available


  92. RUSSO CV, Sacca F, Braca S, Sansone M, et al
    Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
    Cephalalgia. 2023;43:3331024231161809.
    PubMed     Abstract available


  93. OLESEN J
    Classification of migraine and tension-type headache.
    Cephalalgia. 2023;43:3331024221139238.
    PubMed    


  94. CROWE HM, Wesselink AK, Hatch EE, Wise LA, et al
    Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study.
    Cephalalgia. 2023;43:3331024231161746.
    PubMed     Abstract available


  95. SAKAI F, Igarashi H, Yokoyama M, Begasse de Dhaem O, et al
    Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees.
    Cephalalgia. 2023;43:3331024231165682.
    PubMed     Abstract available


    March 2023
  96. MESSINA R, Huessler EM, Puledda F, Haghdoost F, et al
    Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Cephalalgia. 2023;43:3331024231152169.
    PubMed     Abstract available


  97. MYKLAND MS, Uglem M, Bjork MH, Matre D, et al
    Effects of insufficient sleep on sensorimotor processing in migraine: A randomised, blinded crossover study of event related beta oscillations.
    Cephalalgia. 2023;43:3331024221148398.
    PubMed     Abstract available


  98. PULEDDA F, Tassorelli C, Diener HC
    New migraine drugs.
    Cephalalgia. 2023;43:3331024221144784.
    PubMed    


  99. LEE MJ, Peng KP
    Other primary headaches: Distinct clinical features and uncertain pathophysiology.
    Cephalalgia. 2023;43:3331024221147870.
    PubMed    


  100. PULEDDA F, Younis S, Huessler EM, Haghdoost F, et al
    Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature.
    Cephalalgia. 2023;43:3331024231151419.
    PubMed     Abstract available


  101. CARLSEN LN, Hansen CS, Kogelman LJA, Werge TM, et al
    DNA-methylation and immunological response in medication overuse headache.
    Cephalalgia. 2023;43:3331024221147482.
    PubMed     Abstract available


  102. EVERS S
    Cephalalgia - The early history.
    Cephalalgia. 2023;43:3331024221148128.
    PubMed     Abstract available


  103. MYKLAND MS, Uglem M, Stovner LJ, Brenner E, et al
    Insufficient sleep may alter cortical excitability near the migraine attack: A blinded TMS crossover study.
    Cephalalgia. 2023;43:3331024221148391.
    PubMed     Abstract available


  104. ASHINA S, Melo-Carrillo A, Szabo E, Borsook D, et al
    Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202).
    Cephalalgia. 2023;43:3331024221147881.
    PubMed     Abstract available


    February 2023
  105. RAFFAELLI B, De Icco R, Corrado M, Terhart M, et al
    Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
    Cephalalgia. 2023;43:3331024221137091.
    PubMed     Abstract available


  106. AL-KARAGHOLI MA, Kalatharan V, Ghanizada H, Gram C, et al
    Prolactin in headache and migraine: A systematic review of clinical studies.
    Cephalalgia. 2023;43:3331024221136286.
    PubMed     Abstract available


  107. LEE MJ, Al-Karagholi MA, Reuter U
    New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy.
    Cephalalgia. 2023;43:3331024221146315.
    PubMed     Abstract available


  108. HARDER AV, Terwindt GM, Nyholt DR, van den Maagdenberg AM, et al
    Migraine genetics: Status and road forward.
    Cephalalgia. 2023;43:3331024221145962.
    PubMed     Abstract available


  109. GALLARDO VJ, Vila-Pueyo M, Pozo-Rosich P
    The impact of epigenetic mechanisms in migraine: Current knowledge and future directions.
    Cephalalgia. 2023;43:3331024221145916.
    PubMed     Abstract available


  110. NIKOLOVA S, Chong CD, Dumkrieger GM, Li J, et al
    Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine.
    Cephalalgia. 2023;43:3331024221144783.
    PubMed     Abstract available


  111. KWON S, Lee MJ, Kim M
    Epicranial headache part 1: Primary stabbing headache.
    Cephalalgia. 2023;43:3331024221146985.
    PubMed     Abstract available


  112. SCHRAMM S, Borner C, Reichert M, Baum T, et al
    Functional magnetic resonance imaging in migraine: A systematic review.
    Cephalalgia. 2023;43:3331024221128278.
    PubMed     Abstract available


  113. DE BOER I, Verhagen IE, Souza MNP, Ashina M, et al
    Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies.
    Cephalalgia. 2023;43:3331024221143773.
    PubMed     Abstract available


  114. RUIZ M, Cocores A, Tosti A, Goadsby PJ, et al
    Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review.
    Cephalalgia. 2023;43:3331024221143538.
    PubMed     Abstract available


  115. CHOWDHURY D, Tomar A, Deorari V, Duggal A, et al
    Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study.
    Cephalalgia. 2023;43:3331024221143541.
    PubMed     Abstract available


  116. LIPTON RB, Blumenfeld A, Jensen CM, Croop R, et al
    Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
    Cephalalgia. 2023;43:3331024221141686.
    PubMed     Abstract available


  117. MEISE R, Carvalho GF, Thiel C, Luedtke K, et al
    Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine: A randomized controlled trial.
    Cephalalgia. 2023;43:3331024221144781.
    PubMed     Abstract available


  118. TASNIM S, Wilson SG, Walsh JP, Nyholt DR, et al
    Shared genetics and causal relationships between migraine and thyroid function traits.
    Cephalalgia. 2023;43:3331024221139253.
    PubMed     Abstract available


  119. BEGASSE DE DHAEM O, Takizawa T, Dodick DW
    Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks.
    Cephalalgia. 2023;43:3331024221137092.
    PubMed     Abstract available


  120. VILA-PUEYO M, Cuenca-Leon E, Queiros AC, Kulis M, et al
    Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization.
    Cephalalgia. 2023;43:3331024221146317.
    PubMed     Abstract available


    January 2023
  121. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
    Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache.
    Cephalalgia. 2023;43:3331024221131331.
    PubMed     Abstract available


  122. SCUTELNIC A, Petroulia V, Schraml L, Jung S, et al
    The "index vein" as a sign for migraine aura in the emergency setting.
    Cephalalgia. 2023;43:3331024221132010.
    PubMed     Abstract available


  123. ACARSOY C, Fani L, Al-Hassany L, Berghout B, et al
    Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study.
    Cephalalgia. 2023;43:3331024221132008.
    PubMed     Abstract available


  124. KURTH T, Rohmann JL
    Studying migraine as a risk factor for stroke: The importance of working with an explicit causal framework.
    Cephalalgia. 2023;43:3331024221132007.
    PubMed    


  125. KLEIN BC, Miceli R, Severt L, McAllister P, et al
    Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
    Cephalalgia. 2023;43:3331024221128250.
    PubMed     Abstract available


  126. PACHECO-BARRIOS K, Velasquez-Rimachi V, Navarro-Flores A, Huerta-Rosario A, et al
    Primary headache disorders in Latin America and the Caribbean: A meta-analysis of population-based studies.
    Cephalalgia. 2023;43:3331024221128265.
    PubMed     Abstract available


  127. CARONNA E, van den Hoek TC, Bolay H, Garcia-Azorin D, et al
    Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review.
    Cephalalgia. 2023;43:3331024221131337.
    PubMed     Abstract available


  128. FURIA A, Liguori R, Donadio V
    Recurrent Painful Ophthalmoplegic Neuropathy: A case report with atypical features and a review of the literature.
    Cephalalgia. 2023;43:3331024221133386.
    PubMed     Abstract available


  129. CHWOLKA M, Goadsby PJ, Gantenbein AR
    Comorbidity or combination - more evidence for cluster-migraine?
    Cephalalgia. 2023;43:3331024221133383.
    PubMed     Abstract available


    November 2022
  130. SAMPATAKAKIS SN, Lymperopoulos L, Mavridis T, Karagiorgis G, et al
    Visual snow: A systematic review and a case series.
    Cephalalgia. 2022;42:1409-1419.
    PubMed     Abstract available


  131. CITAK A, Kilinc E, Torun IE, Ankarali S, et al
    The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system.
    Cephalalgia. 2022;42:1375-1386.
    PubMed     Abstract available


  132. BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
    Galcanezumab modulates Capsaicin-induced C-fiber reactivity.
    Cephalalgia. 2022;42:1331-1338.
    PubMed     Abstract available


    October 2022
  133. MARTINS-OLIVEIRA M, Akerman S, Holland PR, Tavares I, et al
    Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine.
    Cephalalgia. 2022 Oct 18:3331024221110111. doi: 10.1177/03331024221110111.
    PubMed     Abstract available


  134. RIESENBERG R, Gaul C, Stroud CE, Dong Y, et al
    Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
    Cephalalgia. 2022;42.
    PubMed     Abstract available


  135. EVERS S, Holle-Lee D, Schankin CJ, Kull P, et al
    Visual snow syndrome is probably not mediated by CGRP: A case series.
    Cephalalgia. 2022;42.
    PubMed     Abstract available


  136. LANGER LK, Bayley MT, Lawrence DW, Comper P, et al
    Revisiting the ICHD-3 criteria for headache attributed to mild traumatic injury to the head: Insights from the Toronto Concussion Study Analysis of Acute Headaches Following Concussion.
    Cephalalgia. 2022;42.
    PubMed     Abstract available


  137. RAY JC, Pham X, Foster E, Cheema S, et al
    The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature.
    Cephalalgia. 2022;42.
    PubMed     Abstract available


    September 2022
  138. LANTERI-MINET M, Ducros A, Francois C, Olewinska E, et al
    Effectiveness of onabotulinumtoxinA (BOTOX(R)) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.
    Cephalalgia. 2022 Sep 8:3331024221123058. doi: 10.1177/03331024221123058.
    PubMed     Abstract available


  139. TSAO YC, Wang YF, Fuh JL, Chen WT, et al
    Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura.
    Cephalalgia. 2022 Sep 6:3331024221123074. doi: 10.1177/03331024221123074.
    PubMed     Abstract available


  140. KELLIER DJ, Marquez de Prado B, Haagen D, Grabner P, et al
    Development of a text message-based headache diary in adolescents and children.
    Cephalalgia. 2022;42:1013-1021.
    PubMed     Abstract available


    August 2022
  141. MACGREGOR EA, Komori M, Krege JH, Baygani S, et al
    Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
    Cephalalgia. 2022 Aug 18:3331024221118929. doi: 10.1177/03331024221118929.
    PubMed     Abstract available


  142. THURAIAIYAH J, Erritzoe-Jervild M, Al-Khazali HM, Schytz HW, et al
    The role of cytokines in migraine: A systematic review.
    Cephalalgia. 2022 Aug 12:3331024221118924. doi: 10.1177/03331024221118924.
    PubMed     Abstract available


  143. HENDRIKSE ER, Rees TA, Tasma Z, Le Foll C, et al
    Calcitonin receptor antibody validation and expression in the rodent brain.
    Cephalalgia. 2022;42:815-826.
    PubMed     Abstract available


  144. STRASSMAN AM, Melo-Carrillo A, Houle TT, Adams A, et al
    Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
    Cephalalgia. 2022;42:933-943.
    PubMed     Abstract available


  145. THUNSTEDT DC, Schmutzer M, Fabritius MP, Thorsteinsdottir J, et al
    Headache characteristics and postoperative course in Chiari I malformation.
    Cephalalgia. 2022;42:879-887.
    PubMed     Abstract available


    July 2022
  146. IKUMI N, Cerda-Company X, Marti-Marca A, Vila-Ballo A, et al
    Avoidance behaviour modulates but does not condition phonophobia in migraine.
    Cephalalgia. 2022 Jul 9:3331024221111772. doi: 10.1177/03331024221111772.
    PubMed     Abstract available


  147. OLESEN J
    Personal view: Modelling pain mechanisms of migraine without aura.
    Cephalalgia. 2022 Jul 7:3331024221111529. doi: 10.1177/03331024221111529.
    PubMed     Abstract available


  148. STEINER TJ, Terwindt GM, Katsarava Z, Pozo-Rosich P, et al
    Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process.
    Cephalalgia. 2022 Jul 5:3331024221110102. doi: 10.1177/03331024221110102.
    PubMed     Abstract available


  149. VIGANO A, Toscano M, Petolicchio B, Bianchi A, et al
    Letter to the editor regarding "Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial".
    Cephalalgia. 2022 Jul 3:3331024221111528. doi: 10.1177/03331024221111528.
    PubMed    


  150. BRANDT RB, Cnossen VM, Doesborg PG, Coo IF, et al
    Unilateral increased visual sensitivity in cluster headache: a cross-sectional study.
    Cephalalgia. 2022;42:722-729.
    PubMed     Abstract available


  151. ZHOU Y, Zhang F, Starcevic Manning M, Hu Z, et al
    Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
    Cephalalgia. 2022;42:749-760.
    PubMed     Abstract available


  152. IANNONE LF, De Cesaris F, Ferrari A, Benemei S, et al
    Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
    Cephalalgia. 2022 Jul 1:3331024221111526. doi: 10.1177/03331024221111526.
    PubMed     Abstract available


    June 2022
  153. MAKAREVICIUS G, Ryliskiene K
    Successful treatment of primary headache associated with sexual activity using erenumab: Case report.
    Cephalalgia. 2022;42:680-683.
    PubMed     Abstract available


  154. OLIVEIRA R, Placido M, Pereira L, Machado S, et al
    Headaches and the use of personal protective equipment in the general population during the COVID-19 pandemic.
    Cephalalgia. 2022;42:608-617.
    PubMed     Abstract available


  155. PENSATO U, Baraldi C, Favoni V, Mascarella D, et al
    Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
    Cephalalgia. 2022;42:645-653.
    PubMed     Abstract available


  156. RAIBIN K, Markus TE
    Cutaneous allodynia in pediatric and adolescent patients and their mothers: A comparative study.
    Cephalalgia. 2022;42:579-589.
    PubMed     Abstract available


    May 2022
  157. SUDAT SE, Jacobson AS, Avins AL, Lipton RB, et al
    A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.
    Cephalalgia. 2022 May 31:3331024221104180. doi: 10.1177/03331024221104180.
    PubMed     Abstract available


  158. CHRISTENSEN CG, Techlo TR, Kogelman LJ, Wegner Thorner L, et al
    Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria.
    Cephalalgia. 2022 May 29:3331024221094548. doi: 10.1177/03331024221094548.
    PubMed     Abstract available


  159. EVERS S, Frese A, Summ O, Husstedt IW, et al
    Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study.
    Cephalalgia. 2022 May 27:3331024221103815. doi: 10.1177/03331024221103815.
    PubMed     Abstract available


  160. MOUAANAKI SA, Carlsen LN, Bendtsen L, Jensen RH, et al
    Treatment experiences and clinical characteristics in migraine and tension-type headache patients before the first visit to a tertiary headache center.
    Cephalalgia. 2022 May 27:3331024221104178. doi: 10.1177/03331024221104178.
    PubMed     Abstract available


  161. VERHAGEN IE, Spaink HA, van der Arend BW, van Casteren DS, et al
    Validation of diagnostic ICHD-3 criteria for menstrual migraine.
    Cephalalgia. 2022 May 6:3331024221099031. doi: 10.1177/03331024221099031.
    PubMed     Abstract available


  162. HELFENSTEIN C, Strupf M, Stefke A, Fraunberger B, et al
    Cyclic changes of sensory parameters in migraine patients.
    Cephalalgia. 2022 May 6:3331024221097932. doi: 10.1177/03331024221097932.
    PubMed     Abstract available


  163. NOSER AE, Klages KL, Gamwell KL, Brammer CN, et al
    A systematic evaluation of primary headache management apps leveraging behavior change techniques.
    Cephalalgia. 2022;42:510-523.
    PubMed     Abstract available


  164. CHIANG CC, Shahid AH, Harriott AM, Tietjen GE, et al
    Evaluation and treatment of headache associated with moyamoya disease - a narrative review.
    Cephalalgia. 2022;42:542-552.
    PubMed     Abstract available


    April 2022
  165. GEPPETTI P, De Cesaris F, Benemei S, Cortelli P, et al
    Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.
    Cephalalgia. 2022 Apr 26:3331024221093712. doi: 10.1177/03331024221093712.
    PubMed     Abstract available


  166. MOHAMAD SAFIAI NI, Mohamad NA, Basri H, Inche Mat LN, et al
    High-frequency repetitive transcranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: A systematic review and meta-analysis.
    Cephalalgia. 2022 Apr 17:3331024221092423. doi: 10.1177/03331024221092423.
    PubMed     Abstract available


  167. PAN LH, Wang YF, Ling YH, Lai KL, et al
    Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study.
    Cephalalgia. 2022 Apr 11:3331024221080572. doi: 10.1177/03331024221080572.
    PubMed     Abstract available


  168. NIKOLOVA S, Schwedt TJ, Li J, Wu T, et al
    T2* reduction in patients with acute post-traumatic headache.
    Cephalalgia. 2022;42.
    PubMed     Abstract available


    March 2022
  169. DI ANTONIO S, Arendt-Nielsen L, Ponzano M, Bovis F, et al
    Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients.
    Cephalalgia. 2022 Mar 25:3331024221082506. doi: 10.1177/03331024221082506.
    PubMed     Abstract available


  170. PETRUSIC I, Jovanovic V, Kovic V, Savic AM, et al
    P3 latency as a biomarker for the complexity of migraine with aura: Event-related potential study.
    Cephalalgia. 2022 Mar 25:3331024221090204. doi: 10.1177/03331024221090204.
    PubMed     Abstract available


  171. BUTT JH, S Eddelien H, Kruuse C
    The headache and aura-inducing effects of sildenafil in patients with migraine with aura.
    Cephalalgia. 2022 Mar 25:3331024221088998. doi: 10.1177/03331024221088998.
    PubMed     Abstract available


  172. MCALLISTER P, Kudrow D, Cady R, Hirman J, et al
    Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
    Cephalalgia. 2022 Mar 25:3331024221089567. doi: 10.1177/03331024221089567.
    PubMed     Abstract available


  173. FERNANDEZ-DE-LAS-PENAS C, Navarro-Santana MJ, Curiel-Montero F, Plaza-Manzano G, et al
    Localized and widespread pressure pain hypersensitivity in patients with episodic or chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Mar 25:3331024221084217. doi: 10.1177/03331024221084217.
    PubMed     Abstract available


  174. DIENER HC, McAllister P, Jurgens TP, Kessler Y, et al
    Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
    Cephalalgia. 2022 Mar 25:3331024221076485. doi: 10.1177/03331024221076485.
    PubMed     Abstract available


  175. ASHINA M, McAllister P, Cady R, Hirman J, et al
    Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
    Cephalalgia. 2022 Mar 18:3331024221077646. doi: 10.1177/03331024221077646.
    PubMed     Abstract available


  176. WANG YF, Liao YC, Tzeng YS, Chen SP, et al
    Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura.
    Cephalalgia. 2022 Mar 18:3331024221080891. doi: 10.1177/03331024221080891.
    PubMed     Abstract available


  177. KWON S, Gil YE, Lee MJ
    Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
    Cephalalgia. 2022 Mar 18:3331024221076481. doi: 10.1177/03331024221076481.
    PubMed     Abstract available


  178. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The burden and health care use of patients with migraine and tension-type headache in post-conflict area of Serbia.
    Cephalalgia. 2022 Mar 18:3331024221082061. doi: 10.1177/03331024221082061.
    PubMed     Abstract available


  179. HIRTZ C, Adam G, Raposo N, Fabre N, et al
    Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign.
    Cephalalgia. 2022 Mar 18:3331024221076484. doi: 10.1177/03331024221076484.
    PubMed     Abstract available


  180. THURAIAIYAH J, Kokoti L, Al-Karagholi MA, Ashina M, et al
    Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies.
    Cephalalgia. 2022 Mar 18:3331024221077665. doi: 10.1177/03331024221077665.
    PubMed     Abstract available


  181. CHOWDHURY D, Mundra A, Datta D, Duggal A, et al
    Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial.
    Cephalalgia. 2022 Mar 8:3331024221082077. doi: 10.1177/03331024221082077.
    PubMed     Abstract available


  182. VAZ JM, Alves BM, Duarte DB, Marques LA, et al
    Quality appraisal of existing guidelines for the management of headache disorders by the AGREE II's method.
    Cephalalgia. 2022;42:239-249.
    PubMed     Abstract available


    February 2022
  183. MATAMALA-GOMEZ M, Bottiroli S, Sances G, Allena M, et al
    Facial expressions modulate pain perception in patients with chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075081. doi: 10.1177/03331024221075081.
    PubMed     Abstract available


  184. SEBASTIANELLI G, Abagnale C, Casillo F, Cioffi E, et al
    Bimodal sensory integration in migraine: A study of the effect of visual stimulation on somatosensory evoked cortical responses.
    Cephalalgia. 2022 Feb 15:3331024221075073. doi: 10.1177/03331024221075073.
    PubMed     Abstract available


  185. KIM J, Park CG, Chu MK
    Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075616. doi: 10.1177/03331024221075616.
    PubMed     Abstract available


  186. STOVNER LJ, Hagen K, Tronvik E, Bruvik Gravdahl G, et al
    FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024211067775. doi: 10.1177/03331024211067775.
    PubMed     Abstract available


  187. NUOTTAMO ME, Happola P, Artto V, Hautakangas H, et al
    NCOR2 is a novel candidate gene for migraine-epilepsy phenotype.
    Cephalalgia. 2022 Feb 15:3331024211068065. doi: 10.1177/03331024211068065.
    PubMed     Abstract available


  188. AL-KHAZALI HM, Younis S, Al-Sayegh Z, Ashina S, et al
    Prevalence of neck pain in migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Feb 15:3331024211068073. doi: 10.1177/03331024211068073.
    PubMed     Abstract available


  189. MESSLINGER K, Neuhuber W, May A
    Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19.
    Cephalalgia. 2022;42:176-180.
    PubMed     Abstract available


    January 2022
  190. NAJIB U, Smith T, Hindiyeh N, Saper J, et al
    Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
    Cephalalgia. 2022 Jan 9:3331024211068813. doi: 10.1177/03331024211068813.
    PubMed     Abstract available


  191. MCGINLEY JS, Houts CR, Wirth RJ, Lipton RB, et al
    Measuring headache day severity using multiple features in daily diary designs.
    Cephalalgia. 2022;42:53-62.
    PubMed     Abstract available


    December 2021
  192. ELIZAGARAY-GARCIA I, Carvalho GF, Szikszay TM, Adamczyk WM, et al
    Psychophysical testing in chronic migraine and chronic tension type headache: An observational study.
    Cephalalgia. 2021 Dec 7:3331024211060315. doi: 10.1177/03331024211060315.
    PubMed     Abstract available


  193. OLIVEIRA AB, Mercante JPP, Peres MFP, Molina MDCB, et al
    Physical inactivity and headache disorders: Cross-sectional analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Cephalalgia. 2021;41:1467-1485.
    PubMed     Abstract available


  194. NERI I, Menichini D, Monari F, Bascio LS, et al
    Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
    Cephalalgia. 2021;41:1492-1498.
    PubMed     Abstract available


    November 2021
  195. CHRISTENSEN SL, Rasmussen RH, Cour S, Ernstsen C, et al
    Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models.
    Cephalalgia. 2021 Nov 24:3331024211053570. doi: 10.1177/03331024211053570.
    PubMed     Abstract available


  196. MALEKIAN N, Bastani PB, Oveisgharan S, Nabaei G, et al
    Preventive effect of greater occipital nerve block on patients with episodic migraine: A randomized double-blind placebo-controlled clinical trial.
    Cephalalgia. 2021 Nov 17:3331024211058182. doi: 10.1177/03331024211058182.
    PubMed     Abstract available


  197. CHHABRA N, Chiang CC, Di Nome MA, Houghton O, et al
    Migrainous infarction of the eye: Two cases of monocular ischemic complications associated with retinal migraine.
    Cephalalgia. 2021 Nov 17:3331024211056286. doi: 10.1177/03331024211056286.
    PubMed     Abstract available


  198. NEVERDAHL JP, Uglem M, Matre D, Hansen JO, et al
    Pain thresholds and suprathreshold pain after sleep restriction in migraine - A blinded crossover study.
    Cephalalgia. 2021 Nov 17:3331024211056565. doi: 10.1177/03331024211056565.
    PubMed     Abstract available


  199. TOGHA M, Martami F, Jafari E, Ariyanfar S, et al
    The prevalence and characteristics of visceral autonomic symptoms among migraineurs: A population-based study.
    Cephalalgia. 2021 Nov 17:3331024211056849. doi: 10.1177/03331024211056849.
    PubMed     Abstract available


  200. REUTER U, Ehrlich M, Gendolla A, Heinze A, et al
    Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
    Cephalalgia. 2021 Nov 7:3331024211053571. doi: 10.1177/03331024211053571.
    PubMed     Abstract available


  201. PARAKRAMAWEERA R, Evans RW, Schor LI, Pearson SM, et al
    A brief diagnostic screen for cluster headache: Creation and initial validation of the Erwin Test for Cluster Headache.
    Cephalalgia. 2021;41:1298-1309.
    PubMed     Abstract available


    October 2021
  202. HAPPOLA P, Gormley P, Nuottamo ME, Artto V, et al
    Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.
    Cephalalgia. 2021 Oct 14:3331024211045651. doi: 10.1177/03331024211045651.
    PubMed     Abstract available


  203. OVEREEM LH, Peikert A, Hofacker MD, Kamm K, et al
    Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Cephalalgia. 2021 Oct 13:3331024211048765. doi: 10.1177/03331024211048765.
    PubMed     Abstract available


  204. MESSINA R, Rocca MA, Valsasina P, Misci P, et al
    Clinical correlates of hypothalamic functional changes in migraine patients.
    Cephalalgia. 2021 Oct 13:3331024211046618. doi: 10.1177/03331024211046618.
    PubMed     Abstract available


  205. KANG L, Tang W, Zhang Y, Zhang M, et al
    The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice.
    Cephalalgia. 2021 Oct 13:3331024211050036. doi: 10.1177/03331024211050036.
    PubMed     Abstract available


  206. REUTER U, Krege JH, Lombard L, Gomez Valderas E, et al
    Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Cephalalgia. 2021 Oct 13:3331024211048507. doi: 10.1177/03331024211048507.
    PubMed     Abstract available


  207. ALPUENTE A, Gallardo VJ, Asskour L, Caronna E, et al
    Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
    Cephalalgia. 2021 Oct 4:3331024211040467. doi: 10.1177/03331024211040467.
    PubMed     Abstract available


  208. FRANK F, Ulmer H, Sidoroff V, Broessner G, et al
    CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2021;41.
    PubMed     Abstract available


  209. TANHA HM, Martin NG, Whitfield JB, Nyholt DR, et al
    Association and genetic overlap between clinical chemistry tests and migraine.
    Cephalalgia. 2021;41.
    PubMed     Abstract available


  210. GONZALEZ-QUINTANILLA V, Perez-Pereda S, Gonzalez-Suarez A, Madera J, et al
    Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases.
    Cephalalgia. 2021;41.
    PubMed     Abstract available


  211. VAN CASTEREN DS, Verhagen IE, de Boer I, de Vries Lentsch S, et al
    E-diary use in clinical headache practice: A prospective observational study.
    Cephalalgia. 2021;41.
    PubMed     Abstract available


    September 2021
  212. LOBO R, Wang M, Lobo S, Bahra A, et al
    Time to retire 'New daily persistent headache': Mode of onset of chronic migraine and tension-type headache.
    Cephalalgia. 2021 Sep 27:3331024211044440. doi: 10.1177/03331024211044440.
    PubMed     Abstract available


  213. KIM S, Lee SB, Hong YJ, Kim Y, et al
    The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea.
    Cephalalgia. 2021 Sep 27:3331024211044441. doi: 10.1177/03331024211044441.
    PubMed     Abstract available


  214. CHOWDHURY D, Bansal L, Duggal A, Datta D, et al
    TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.
    Cephalalgia. 2021 Sep 27:3331024211047454. doi: 10.1177/03331024211047454.
    PubMed     Abstract available


  215. RAFFAELLI B, Terhart M, Overeem LH, Mecklenburg J, et al
    Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
    Cephalalgia. 2021 Sep 27:3331024211046617. doi: 10.1177/03331024211046617.
    PubMed     Abstract available


  216. INAN LE, Inan N
    Greater occipital nerve block in migraine may have a place in migraine treatment.
    Cephalalgia. 2021 Sep 23:3331024211045644. doi: 10.1177/03331024211045644.
    PubMed    


  217. BOTTIROLI S, Galli F, Ballante E, Pazzi S, et al
    Validity of the Severity of Dependence Scale for detecting dependence behaviours in chronic migraine with medication overuse.
    Cephalalgia. 2021 Sep 20:3331024211039817. doi: 10.1177/03331024211039817.
    PubMed     Abstract available


  218. PUTANANICKAL N, Gross EC, Orsini AL, Schmidt S, et al
    Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
    Cephalalgia. 2021 Sep 20:3331024211043792. doi: 10.1177/03331024211043792.
    PubMed     Abstract available



  219. CORRIGENDUM to 'Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis'.
    Cephalalgia. 2021 Sep 14:3331024211042798. doi: 10.1177/03331024211042798.
    PubMed    


  220. SCHWEDT TJ, Lipton RB, Ailani J, Silberstein SD, et al
    Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Cephalalgia. 2021 Sep 14:3331024211042385. doi: 10.1177/03331024211042385.
    PubMed     Abstract available


  221. IKEGAMI D, Navratilova E, Yue X, Moutal A, et al
    A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
    Cephalalgia. 2021 Sep 12:3331024211039813. doi: 10.1177/03331024211039813.
    PubMed     Abstract available


    August 2021
  222. LIPTON RB, Dodick DW, Kudrow D, Reuter U, et al
    Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Cephalalgia. 2021 Aug 18:3331024211028966. doi: 10.1177/03331024211028966.
    PubMed     Abstract available


  223. TFELT-HANSEN P, Jorgensen K, Diener HC
    Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.
    Cephalalgia. 2021 Aug 18:3331024211029939. doi: 10.1177/03331024211029939.
    PubMed     Abstract available


  224. CHRISTENSEN SL, Rasmussen RH, Ernstsen C, La Cour S, et al
    CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine.
    Cephalalgia. 2021 Aug 18:3331024211038884. doi: 10.1177/03331024211038884.
    PubMed     Abstract available


  225. PENG KP, Schellong M, May A
    Aura in trigeminal autonomic cephalalgia is probably mediated by comorbid migraine with aura.
    Cephalalgia. 2021 Aug 18:3331024211030499. doi: 10.1177/03331024211030499.
    PubMed     Abstract available


  226. GIL-GOUVEIA R, Oliveira AG
    Are PROMs passing the message? A reflection with real-life migraine patients.
    Cephalalgia. 2021 Aug 18:3331024211034509. doi: 10.1177/03331024211034509.
    PubMed     Abstract available


  227. ROZEN TD, Bhatt AA
    Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention.
    Cephalalgia. 2021 Aug 18:3331024211037277. doi: 10.1177/03331024211037277.
    PubMed     Abstract available


  228. BEIER D, Callesen HE, Carlsen LN, Birkefoss K, et al
    Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis.
    Cephalalgia. 2021 Aug 18:3331024211034489. doi: 10.1177/03331024211034489.
    PubMed     Abstract available


  229. MARTINELLI D, Arceri S, De Icco R, Allena M, et al
    BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.
    Cephalalgia. 2021 Aug 18:3331024211034508. doi: 10.1177/03331024211034508.
    PubMed     Abstract available


  230. MCGINLEY JS, Savord A, Houts CR, Wirth RJ, et al
    What do people want to know about "Growing Up with Migraine"? Results of a preference survey of people with lived experience to guide future research.
    Cephalalgia. 2021 Aug 18:3331024211038526. doi: 10.1177/03331024211038526.
    PubMed     Abstract available


  231. AL-HASSANY L, Vries T, Carpay JA, MaassenVanDenBrink A, et al
    Could erectile dysfunction be a side effect of CGRP inhibition? A case report.
    Cephalalgia. 2021 Aug 18:3331024211037304. doi: 10.1177/03331024211037304.
    PubMed     Abstract available


  232. REIDY BL, Peugh J, Hershey AD, Coffey CS, et al
    Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial.
    Cephalalgia. 2021 Aug 17:3331024211033551. doi: 10.1177/03331024211033551.
    PubMed     Abstract available


  233. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The first prevalence study of primary headaches in adults in a post-conflict area of Serbia.
    Cephalalgia. 2021;41:959-967.
    PubMed     Abstract available


  234. HUTCHINSON S, Silberstein SD, Blumenfeld AM, Lipton RB, et al
    Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
    Cephalalgia. 2021;41:979-990.
    PubMed     Abstract available


  235. MEHTA DG, Garza I, Robertson CE
    Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities.
    Cephalalgia. 2021;41:1015-1026.
    PubMed     Abstract available


    July 2021
  236. TFELT-HANSEN P
    Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review.
    Cephalalgia. 2021 Jul 18:3331024211028959. doi: 10.1177/03331024211028959.
    PubMed     Abstract available


  237. ROXAS A JR, Quiles LE, Wang SJ
    Delivery of care for migraine in the Asian Oceanian region: A cross-sectional study.
    Cephalalgia. 2021 Jul 18:3331024211024153. doi: 10.1177/03331024211024153.
    PubMed     Abstract available


  238. CERAMI C, Crespi C, Bottiroli S, Santi GC, et al
    High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients.
    Cephalalgia. 2021 Jul 13:3331024211027568. doi: 10.1177/03331024211027568.
    PubMed     Abstract available


  239. AKERMAN S, Salvemini D, Romero-Reyes M
    Targeting reactive nitroxidative species in preclinical models of migraine.
    Cephalalgia. 2021 Jul 13:3331024211017884. doi: 10.1177/03331024211017884.
    PubMed     Abstract available


  240. DAVIDSSON OB, Olofsson IA, Kogelman LJ, Andersen MA, et al
    Twenty-five years of triptans - a nationwide population study.
    Cephalalgia. 2021;41:894-904.
    PubMed     Abstract available


    June 2021
  241. MACKENZIE KD, Stratton JR
    Response to letter to the Editor: Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021563. doi: 10.1177/03331024211021563.
    PubMed    


  242. XU C, Bussiere J
    Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021569. doi: 10.1177/03331024211021569.
    PubMed    


  243. WANG SJ, Roxas AA Jr, Saravia B, Kim BK, et al
    Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
    Cephalalgia. 2021 Jun 25:3331024211024160. doi: 10.1177/03331024211024160.
    PubMed     Abstract available


  244. GERSTL L, Tadych N, Heinen F, Kainz C, et al
    Migraine and the development of additional psychiatric and pain disorders in the transition from adolescence to adulthood.
    Cephalalgia. 2021 Jun 23:3331024211021792. doi: 10.1177/03331024211021792.
    PubMed     Abstract available


  245. BENBOW T, Cairns BE
    Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?
    Cephalalgia. 2021 Jun 20:3331024211017882. doi: 10.1177/03331024211017882.
    PubMed     Abstract available


  246. FRESE A, Summ O, Evers S
    CGRP release in an experimental human trigeminal pain model.
    Cephalalgia. 2021 Jun 20:3331024211017250. doi: 10.1177/03331024211017250.
    PubMed     Abstract available


  247. LENGYEL M, Hajdu D, Dobolyi A, Rosta J, et al
    TRESK background potassium channel modifies the TRPV1-mediated nociceptor excitability in sensory neurons.
    Cephalalgia. 2021;41:827-838.
    PubMed     Abstract available


  248. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
    A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences.
    Cephalalgia. 2021;41:810-820.
    PubMed     Abstract available


    May 2021
  249. COHEN-BARAK O, Radivojevic A, Jones A, Fiedler-Kelly J, et al
    Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
    Cephalalgia. 2021 May 17:3331024211007789. doi: 10.1177/03331024211007789.
    PubMed     Abstract available


  250. GANTENBEIN AR, Agosti R, Gobbi C, Flugel D, et al
    Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.
    Cephalalgia. 2021 May 17:3331024211014616. doi: 10.1177/03331024211014616.
    PubMed     Abstract available


  251. TASSORELLI C, Diener HC, Silberstein SD, Dodick DW, et al
    Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
    Cephalalgia. 2021 May 14:3331024211010413. doi: 10.1177/03331024211010413.
    PubMed     Abstract available


  252. WILKINS AJ, Haigh SM, Mahroo OA, Plant GT, et al
    Photophobia in migraine: A symptom cluster?
    Cephalalgia. 2021 May 14:3331024211014633. doi: 10.1177/03331024211014633.
    PubMed     Abstract available


  253. PAZDERA L, Cohen JM, Ning X, Campos VR, et al
    Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
    Cephalalgia. 2021 May 14:3331024211008401. doi: 10.1177/03331024211008401.
    PubMed     Abstract available


  254. LIPTON RB, Burstein R, Buse DC, Dodick DW, et al
    Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
    Cephalalgia. 2021 May 13:3331024211010305. doi: 10.1177/03331024211010305.
    PubMed     Abstract available



  255. CORRIGENDUM to 'Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN'.
    Cephalalgia. 2021 May 5:3331024211015848. doi: 10.1177/03331024211015848.
    PubMed    


  256. DIENER HC, Ashina M, Ritter S, Paiva Da Silva Lima G, et al
    Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
    Cephalalgia. 2021 May 3:3331024211010308. doi: 10.1177/03331024211010308.
    PubMed     Abstract available


  257. YOUNG AS, Nham B, Bradshaw AP, Calic Z, et al
    Clinical, oculographic, and vestibular test characteristics of vestibular migraine.
    Cephalalgia. 2021 May 2:3331024211006042. doi: 10.1177/03331024211006042.
    PubMed     Abstract available


  258. SCHWEDT TJ, Sahai-Srivastava S, Murinova N, Birlea M, et al
    Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial.
    Cephalalgia. 2021 May 2:3331024211006903. doi: 10.1177/03331024211006903.
    PubMed     Abstract available


    April 2021
  259. CHONG CD, Berisha V, Ross K, Kahn M, et al
    Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data.
    Cephalalgia. 2021 Apr 29:333102421991819. doi: 10.1177/0333102421991819.
    PubMed     Abstract available


  260. POHL H, Benemei S, Garcia-Azorin D, Dixon J, et al
    Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments.
    Cephalalgia. 2021 Apr 19:3331024211006048. doi: 10.1177/03331024211006048.
    PubMed     Abstract available


  261. RAOOF N, Hoffmann J
    Diagnosis and treatment of idiopathic intracranial hypertension.
    Cephalalgia. 2021;41:472-478.
    PubMed     Abstract available


  262. CERIANI CE, Silberstein SD
    Headache and rhinosinusitis: A review.
    Cephalalgia. 2021;41:453-463.
    PubMed     Abstract available


    March 2021
  263. ROTHROCK JF, Diener HC
    Headache secondary to cerebrovascular disease.
    Cephalalgia. 2021 Mar 18:333102421999045. doi: 10.1177/0333102421999045.
    PubMed     Abstract available


  264. ZHANG Y, Zhao X, Wang Y, Dong Z, et al
    Prevalence and characteristics of cough headache in a Chinese respiratory clinic.
    Cephalalgia. 2021;41:366-374.
    PubMed     Abstract available


  265. VINOGRADOVA LV, Suleymanova EM, Medvedeva TM
    Transient loss of interhemispheric functional connectivity following unilateral cortical spreading depression in awake rats.
    Cephalalgia. 2021;41:353-365.
    PubMed     Abstract available


    February 2021
  266. SHAH R, Assis F, Narasimhan B, Khachadourian V, et al
    Trans-nasal high-flow dehumidified air in acute migraine headaches: A randomized controlled trial.
    Cephalalgia. 2021 Feb 25:333102421997766. doi: 10.1177/0333102421997766.
    PubMed     Abstract available


  267. WANG X, Yin Z, Lian Y, Xu Y, et al
    Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients.
    Cephalalgia. 2021 Feb 25:333102421997850. doi: 10.1177/0333102421997850.
    PubMed     Abstract available


  268. BHAKTA M, Vuong T, Taura T, Wilson DS, et al
    Migraine therapeutics differentially modulate the CGRP pathway.
    Cephalalgia. 2021 Feb 24:333102420983282. doi: 10.1177/0333102420983282.
    PubMed     Abstract available


  269. SOLLMANN N, Schandelmaier P, Weidlich D, Borner C, et al
    Patients with episodic migraine show increased T2 values of the trapezius muscles - an investigation by quantitative high-resolution magnetic resonance imaging.
    Cephalalgia. 2021 Feb 20:333102421996374. doi: 10.1177/0333102421996374.
    PubMed     Abstract available


  270. SOUTHWELL J, Afridi SK
    The burden of migraine on acute and emergency services in a London teaching hospital.
    Cephalalgia. 2021 Feb 18:333102420981734. doi: 10.1177/0333102420981734.
    PubMed     Abstract available


  271. DE TOMMASO M, Delussi M, Gentile E, Ricci K, et al
    Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients.
    Cephalalgia. 2021 Feb 16:333102421996345. doi: 10.1177/0333102421996345.
    PubMed     Abstract available


  272. DRELLIA K, Kokoti L, Deligianni CI, Papadopoulos D, et al
    Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
    Cephalalgia. 2021 Feb 10:333102421989601. doi: 10.1177/0333102421989601.
    PubMed     Abstract available


  273. WIENHOLTZ NKF, Christensen CE, Zhang DG, Coskun H, et al
    Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
    Cephalalgia. 2021 Feb 10:333102420975395. doi: 10.1177/0333102420975395.
    PubMed     Abstract available


  274. TCHIVILEVA IE, Ohrbach R, Fillingim RB, Lim PF, et al
    Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
    Cephalalgia. 2021 Feb 9:333102421989268. doi: 10.1177/0333102421989268.
    PubMed     Abstract available


  275. ASHINA M, Reuter U, Smith T, Krikke-Workel J, et al
    Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
    Cephalalgia. 2021 Feb 4:333102421989232. doi: 10.1177/0333102421989232.
    PubMed     Abstract available


  276. LISICKI M, Figuerola ML, Bonamico L, Lew D, et al
    The prevalence of migraine in Argentina: A reappraisal.
    Cephalalgia. 2021 Feb 1:333102421989262. doi: 10.1177/0333102421989262.
    PubMed     Abstract available


  277. CHO S, Cho SJ, Lee MJ, Park JW, et al
    Clinical characteristics of pre-attack symptoms in cluster headache: A large series of Korean patients.
    Cephalalgia. 2021;41:227-236.
    PubMed     Abstract available


    January 2021
  278. DIENER HC, Ashina M, Durand-Zaleski I, Kurth T, et al
    Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.
    Cephalalgia. 2021 Jan 20:333102421989247. doi: 10.1177/0333102421989247.
    PubMed     Abstract available


  279. CATARCI T
    Occipital ischaemic stroke after visual snow phenomenon - a case report.
    Cephalalgia. 2021 Jan 12:333102420985444. doi: 10.1177/0333102420985444.
    PubMed     Abstract available


  280. VERHAGEN IE, van Casteren DS, Lentsch SV, Terwindt GM, et al
    Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study.
    Cephalalgia. 2021 Jan 11:333102420981739. doi: 10.1177/0333102420981739.
    PubMed     Abstract available


  281. KARSAN N, Perez-Rodriguez A, Nagaraj K, Bose PR, et al
    The migraine postdrome: Spontaneous and triggered phenotypes.
    Cephalalgia. 2021 Jan 10:333102420975401. doi: 10.1177/0333102420975401.
    PubMed     Abstract available


  282. MELO-CARRILLO A, Strassman AM, Schain AJ, Adams AM, et al
    Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
    Cephalalgia. 2021;41:17-32.
    PubMed     Abstract available


  283. LEHMAN LL, Bruccoleri R, Danehy A, Swanson J, et al
    Adverse effects of erenumab on cerebral proliferative angiopathy: A case report.
    Cephalalgia. 2021;41:122-126.
    PubMed     Abstract available


    December 2020
  284. ILJAZI A, Ashina H, Zhuang ZA, Lopez Lopez C, et al
    Hypersensitivity to calcitonin gene-related peptide in chronic migraine.
    Cephalalgia. 2020 Dec 15:333102420981666. doi: 10.1177/0333102420981666.
    PubMed     Abstract available


  285. BEGASSE DE DHAEM O, Gharedaghi MH, Bain P, Hettie G, et al
    Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review.
    Cephalalgia. 2020 Dec 10:333102420977852. doi: 10.1177/0333102420977852.
    PubMed     Abstract available


  286. STRANG-KARLSSON S, Alenius S, Nasanen-Gilmore P, Nurhonen M, et al
    Migraine in children and adults born preterm: A nationwide register linkage study.
    Cephalalgia. 2020 Dec 9:333102420978357. doi: 10.1177/0333102420978357.
    PubMed     Abstract available


  287. POZO-ROSICH P, Coppola G, Pascual J, Schwedt TJ, et al
    How does the brain change in chronic migraine? Developing disease biomarkers.
    Cephalalgia. 2020 Dec 8:333102420974359. doi: 10.1177/0333102420974359.
    PubMed     Abstract available


  288. SCHRAMM S, Tenhagen I, Schmidt B, Holle-Lee D, et al
    Prevalence and risk factors of migraine and non-migraine headache in older people - results of the Heinz Nixdorf Recall study.
    Cephalalgia. 2020 Dec 3:333102420977183. doi: 10.1177/0333102420977183.
    PubMed     Abstract available


  289. IRIMIA P, Martinez-Valbuena I, Minguez-Olaondo A, Dominguez-Vivero C, et al
    Interictal amylin levels in chronic migraine patients: A case-control study.
    Cephalalgia. 2020 Dec 3:333102420977106. doi: 10.1177/0333102420977106.
    PubMed     Abstract available


  290. LIPTON RB, Tepper SJ, Silberstein SD, Kudrow D, et al
    Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
    Cephalalgia. 2020 Dec 3:333102420973994. doi: 10.1177/0333102420973994.
    PubMed     Abstract available


  291. WOOD ME, Burch RC, Hernandez-Diaz S
    Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine.
    Cephalalgia. 2020 Dec 3:333102420975394. doi: 10.1177/0333102420975394.
    PubMed     Abstract available


  292. GROENKE BR, Daline IH, Nixdorf DR
    SUNCT/SUNA: Case series presenting in an orofacial pain clinic.
    Cephalalgia. 2020 Dec 3:333102420977292. doi: 10.1177/0333102420977292.
    PubMed     Abstract available


    November 2020
  293. GOADSBY PJ, Blumenfeld AM, Lipton RB, Dodick DW, et al
    Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
    Cephalalgia. 2020 Nov 26:333102420970523. doi: 10.1177/0333102420970523.
    PubMed     Abstract available


  294. GHANIZADA H, Iljazi A, Ashina H, Do TP, et al
    Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers.
    Cephalalgia. 2020 Nov 26:333102420970489. doi: 10.1177/0333102420970489.
    PubMed     Abstract available


  295. ASHINA M, Dolezil D, Bonner JH, Zhou L, et al
    A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
    Cephalalgia. 2020 Nov 24:333102420970889. doi: 10.1177/0333102420970889.
    PubMed     Abstract available


  296. VAN CASTEREN DS, Verhagen IE, Onderwater GL, MaassenVanDenBrink A, et al
    Sex differences in prevalence of migraine trigger factors: A cross-sectional study.
    Cephalalgia. 2020 Nov 17:333102420974362. doi: 10.1177/0333102420974362.
    PubMed     Abstract available


  297. WANG SJ, Wu JW
    Reversion from chronic migraine to episodic migraine: A new outcome measure.
    Cephalalgia. 2020 Nov 17:333102420974004. doi: 10.1177/0333102420974004.
    PubMed    


  298. GOLLION C, Gazagnes J, Fabry V, Barbieux-Guillot M, et al
    Atrial fibrillation and migraine with aura in young adults with ischemic stroke.
    Cephalalgia. 2020 Nov 17:333102420970880. doi: 10.1177/0333102420970880.
    PubMed     Abstract available


  299. CARVALHO GF, Luedtke K, Szikszay TM, Bevilaqua-Grossi D, et al
    Muscle endurance training of the neck triggers migraine attacks.
    Cephalalgia. 2020 Nov 17:333102420970184. doi: 10.1177/0333102420970184.
    PubMed     Abstract available


  300. LACKOVIC J, Price TJ, Dussor G
    De novo protein synthesis is necessary for priming in preclinical models of migraine.
    Cephalalgia. 2020 Nov 17:333102420970514. doi: 10.1177/0333102420970514.
    PubMed     Abstract available


  301. MASTRIA G, Mancini V, Cesare MD, Puma M, et al
    Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit.
    Cephalalgia. 2020 Nov 9:333102420968245. doi: 10.1177/0333102420968245.
    PubMed     Abstract available


  302. DODICK DW, Doty EG, Aurora SK, Ruff DD, et al
    Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
    Cephalalgia. 2020 Nov 3:333102420966658. doi: 10.1177/0333102420966658.
    PubMed     Abstract available


  303. KOPRUSZINSKI CM, Thornton P, Arnold J, Newton P, et al
    Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.
    Cephalalgia. 2020 Nov 1:333102420966581. doi: 10.1177/0333102420966581.
    PubMed     Abstract available


  304. PETRUSIC I, Zidverc-Trajkovic J
    Redefining types of migraine aura.
    Cephalalgia. 2020 Nov 1:333102420970186. doi: 10.1177/0333102420970186.
    PubMed    


  305. LEVINE A, Vanderah TW, Largent-Milnes TM
    An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.
    Cephalalgia. 2020 Nov 1:333102420966984. doi: 10.1177/0333102420966984.
    PubMed     Abstract available


    October 2020
  306. LINSTRA KM, Ibrahimi K, van Casteren DS, Wermer MJ, et al
    Pain perception in women with menstrually-related migraine.
    Cephalalgia. 2020 Oct 21:333102420966977. doi: 10.1177/0333102420966977.
    PubMed     Abstract available


  307. ERNSTSEN C, Christensen SL, Olesen J, Kristensen DM, et al
    No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine.
    Cephalalgia. 2020 Oct 15:333102420963857. doi: 10.1177/0333102420963857.
    PubMed     Abstract available


  308. RIST PM, Bernstein C, Kowalski M, Osypiuk K, et al
    Multimodal chiropractic care for migraine: A pilot randomized controlled trial.
    Cephalalgia. 2020 Oct 13:333102420963844. doi: 10.1177/0333102420963844.
    PubMed     Abstract available


  309. ZELE AJ, Dey A, Adhikari P, Feigl B, et al
    Melanopsin hypersensitivity dominates interictal photophobia in migraine.
    Cephalalgia. 2020 Oct 12:333102420963850. doi: 10.1177/0333102420963850.
    PubMed     Abstract available



  310. Migraine Trust Virtual 2020 - Author index.
    Cephalalgia. 2020;40.
    PubMed    


  311. PERES MF, Evers S
    Using social media and search engine data in headache research.
    Cephalalgia. 2020;40:1274-1275.
    PubMed    


    September 2020
  312. ZAGAMI AS, Shaikh S, Mahns D, Lambert GA, et al
    A potential role for two brainstem nuclei in craniovascular nociception and the triggering of migraine headache.
    Cephalalgia. 2020 Sep 29:333102420960039. doi: 10.1177/0333102420960039.
    PubMed     Abstract available


  313. KOPRUSZINSKI CM, Navratilova E, Swiokla J, Dodick DW, et al
    A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
    Cephalalgia. 2020 Sep 26:333102420959794. doi: 10.1177/0333102420959794.
    PubMed     Abstract available


  314. SMITH JH
    Have you ever experienced a headache of any kind?
    Cephalalgia. 2020;40:1132-1133.
    PubMed    


    July 2020
  315. LIU Y, Wang M, Bian X, Qiu E, et al
    Proposed modified diagnostic criteria for recurrent painful ophthalmoplegic neuropathy: Five case reports and literature review.
    Cephalalgia. 2020 Jul 28:333102420944872. doi: 10.1177/0333102420944872.
    PubMed     Abstract available


    December 2019
  316. HVEDSTRUP J, Kolding LT, Younis S, Ashina M, et al
    Ictal neck pain investigated in the interictal state - a search for the origin of pain.
    Cephalalgia. 2019 Dec 18:333102419896369. doi: 10.1177/0333102419896369.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.